| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.
|
Nat Immunol
|
2007
|
8.33
|
|
2
|
Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response.
|
J Immunol
|
2002
|
2.71
|
|
3
|
Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus.
|
Nat Med
|
2002
|
1.61
|
|
4
|
MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
|
J Pharmacol Exp Ther
|
2008
|
1.23
|
|
5
|
Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction.
|
Circulation
|
2008
|
1.14
|
|
6
|
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
|
Arthritis Res Ther
|
2008
|
1.10
|
|
7
|
Role of microsomal prostaglandin E synthase 1 in the kidney.
|
J Am Soc Nephrol
|
2007
|
1.00
|
|
8
|
Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
|
Eur J Pharmacol
|
2007
|
0.92
|
|
9
|
MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.
|
J Pharmacol Exp Ther
|
2008
|
0.92
|
|
10
|
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
|
J Nucl Med
|
2014
|
0.85
|
|
11
|
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
|
Mol Cancer Ther
|
2013
|
0.81
|
|
12
|
Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha.
|
Mol Med
|
2008
|
0.77
|
|
13
|
Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.
|
Bioorg Med Chem Lett
|
2006
|
0.76
|